Ricevi le ultime notizie sulle azioni Cue Biopharma con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di CUE

Ultime notizie per

Cue Biopharma

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Cue Biopharma Inc

Cuentas Inc

COPPEREX RES CORP by COPPEREX RES CORP

CUE ENERGY RESOURCES LTD by Cue Energy Resources Ltd.

News

Press Releases

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

Earnings

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

Health Care

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Small Cap

Opinion

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

General

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Penny Stocks

Management

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

ALLO

CATX

ONCY

TSX:ONC

VSTM

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Celularity

Clene

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

CEL-SCI

Equillium

FibroGen

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

ImmuCell

MiNK Therapeutics

INmune Bio

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Lantern Pharma

MAIA Biotechnology

Medicus Pharma

MediciNova

OS Therapies

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Serina Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

LUCID CAPITAL MARKETS

Citizens Capital Markets

Stifel

JMP Securities

Piper Sandler

Comments

Cue Biopharma Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO